Biomira files investigational new drug application for PX-478, a novel inhibitor of hypoxia-inducible factor-1 alpha
03 Julio 2007 - 8:00AM
PR Newswire (US)
EDMONTON, July 3 /PRNewswire-FirstCall/ -- Biomira Inc.
(NASDAQ:BIOM) (TSX: BRA) today announced that it has submitted an
investigational new drug (IND) application to the U.S. Food and
Drug Administration for PX-478. PX-478 has been shown in
preclinical studies to inhibit hypoxia-inducible factor (HIF)-1
alpha, a protein that controls the transcription of a number of
genes whose products are important for tumor growth and survival.
In these preclinical studies, PX-478 has produced significant tumor
regression and growth delay in multiple models of human cancers,
including cancers of the lung, breast, prostate, colon, kidney,
pancreas and ovary. "HIF-1 alpha plays a critical role in the
response of tumor cells to low oxygen, a situation seen in tumors
where existing blood vessels are insufficient to supply needed
oxygen," said Dr. Lynn Kirkpatrick, Chief Scientific Officer of
Biomira. "In areas of low oxygen and as tumors grow, they adapt
their metabolism due to decreased oxygen and nutrients and attract
new blood vessels to bring in more oxygen, a process known as
angiogenesis. Both the altered metabolism and angiogenesis are
under the control of HIF-1 alpha. Consequently, HIF-1 alpha is a
drug target that provides a multi-pronged approach for cancer
therapy. We believe that PX-478 will be the first small molecule to
enter clinical development that acts directly to lower HIF-1 alpha
protein levels." "With the filing of this IND for PX-478, we are
advancing the development of another promising compound," said Dr.
Robert L. Kirkman, M.D., President and Chief Executive Officer of
Biomira. "Upon clearance of the IND, we intend to initiate a Phase
1 trial for this compound in the third quarter of 2007. We also are
on track to advance our other pipeline programs, including
initiating another Phase 2 trial for PX-12 and filing an IND for
PX-866 by the end of the year. At that point we will have four
programs in clinical development, reflecting the diversity and
promise of our product pipeline." About PX-478 PX-478 is a potent
inhibitor of HIF-1 alpha, a protein target whose levels are
elevated in a wide range of tumors. The protein is a key factor in
the response of a cancer cell to hypoxia (lack of oxygen),
including the angiogenic cascade that allows tumors to establish
new blood vessels essential to their survival and growth.
Inhibition of angiogenesis is a validated approach to treating
cancer. In preclinical studies, PX-478 demonstrated antitumor
activity when delivered orally and has shown marked tumor
regression and growth inhibition, both of which correlated to the
HIF-1 alpha levels of the tumor models. These models included
ovarian, renal, prostate, colon, pancreatic, lung and breast
cancer, representing a large potential market for this product
candidate. The ability to combine PX-478 with radiation therapy may
further expand the opportunities for this novel compound. About
Biomira Biomira is a biotechnology company specializing in the
development of innovative therapeutic products for the treatment of
cancer. Biomira's goal is to develop and commercialize novel
synthetic vaccines and targeted small molecules that have the
potential to improve the lives and outcomes of cancer patients.
Forward-Looking Statements This press release contains
forward-looking statements, including, without limitation,
statements related to the pre-clinical and clinical development of
PX-478, PX-12 and PX-866; the therapeutic and commercial potential
of PX-478, PX-12 and PX-866; the filing of an investigational new
drug application for PX-478 and PX-866 and the timing thereof; the
initiation of a Phase 1 trial for PX-478; the initiation of a Phase
2 trial for PX-12; and future clinical development plans. Any
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Words such as "believes", "anticipates", "plans", "expects",
"will", "intends", "potential", "possible" and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements are based upon Biomira's current
expectations. Forward-looking statements involve risks and
uncertainties. Various factors could cause actual results to differ
materially from those projected in forward-looking statements,
including those predicting the clinical development of PX-478,
PX-12 and PX-866; the therapeutic and commercial potential of
PX-478, PX-12 and PX-866; the filing of an investigational new drug
application for PX-478 and PX-866 and the timing thereof; the
initiation of a Phase 1 trial for PX-478; the initiation of a Phase
2 trial for PX-12; and future clinical development plans. There can
be no guarantee that the results of earlier trials will be
predictive of either safety or efficacy in future trials. Biomira
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
DATASOURCE: Biomira Inc. CONTACT: Investor and Media Relations
Contact: Stephanie H. Seiler, Ph.D., Gemini BioProjects LLC, (206)
713-0124,
Copyright
Biomira Inc. - Common Shares (MM) (NASDAQ:BIOM)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Biomira Inc. - Common Shares (MM) (NASDAQ:BIOM)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024